CN117820498A - 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒 - Google Patents

包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒 Download PDF

Info

Publication number
CN117820498A
CN117820498A CN202410194213.6A CN202410194213A CN117820498A CN 117820498 A CN117820498 A CN 117820498A CN 202410194213 A CN202410194213 A CN 202410194213A CN 117820498 A CN117820498 A CN 117820498A
Authority
CN
China
Prior art keywords
seq
cd38ecd
tag
recombinant
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410194213.6A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·A·霍尔
P·施温特
乔迪·贝里
温琴佐·法瓦洛罗
伊丽莎白·布思
马泰奥·宾达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Diagnostic Solutions Inc
Original Assignee
Grifols Diagnostic Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc filed Critical Grifols Diagnostic Solutions Inc
Publication of CN117820498A publication Critical patent/CN117820498A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202410194213.6A 2017-08-10 2018-06-01 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒 Pending CN117820498A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10
US62/543788 2017-08-10
CN201880000662.5A CN109790210B (zh) 2017-08-10 2018-06-01 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
PCT/IB2018/053939 WO2019030581A1 (en) 2017-08-10 2018-06-01 COMPOSITIONS, METHODS AND / OR KITS COMPRISING AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880000662.5A Division CN109790210B (zh) 2017-08-10 2018-06-01 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒

Publications (1)

Publication Number Publication Date
CN117820498A true CN117820498A (zh) 2024-04-05

Family

ID=62846219

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410194213.6A Pending CN117820498A (zh) 2017-08-10 2018-06-01 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
CN201880000662.5A Active CN109790210B (zh) 2017-08-10 2018-06-01 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880000662.5A Active CN109790210B (zh) 2017-08-10 2018-06-01 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒

Country Status (18)

Country Link
US (3) US11708418B2 (https=)
EP (3) EP3587445B1 (https=)
JP (3) JP6833851B2 (https=)
KR (2) KR102631281B1 (https=)
CN (2) CN117820498A (https=)
AR (1) AR112357A1 (https=)
AU (2) AU2018313028B2 (https=)
BR (1) BR112020002636A2 (https=)
CA (1) CA3070789A1 (https=)
EA (1) EA202090265A1 (https=)
ES (2) ES2911243T3 (https=)
HU (1) HUE065510T2 (https=)
MX (3) MX2020001489A (https=)
PL (1) PL3587445T3 (https=)
PT (1) PT3587445T (https=)
TW (1) TW201910349A (https=)
UY (1) UY37757A (https=)
WO (1) WO2019030581A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke
US11746140B2 (en) * 2018-02-20 2023-09-05 F. Hoffman-La Roche Ag Composition comprising recombinant GPlbα receptor protein
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
CN116635420A (zh) * 2020-09-10 2023-08-22 英创远达制药公司 血液筛查方法
KR20230066404A (ko) 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
WO2024172419A1 (ko) * 2023-02-16 2024-08-22 주식회사 디엔티 Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2185589T3 (pl) * 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US9926373B2 (en) * 2012-04-27 2018-03-27 Novo Nordisk A/S Human CD30 ligand antigen binding proteins
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
EP3221358B1 (en) * 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
JP6649941B2 (ja) * 2015-02-16 2020-02-19 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
US9944679B2 (en) * 2015-03-16 2018-04-17 The Catholic University Of America Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
PE20171790A1 (es) * 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
AU2016352676A1 (en) * 2015-11-10 2018-05-31 University Medical Center Hamburg - Eppendorf ANTIGEN-binding polypeptides directed against CD38
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke

Also Published As

Publication number Publication date
JP7289328B2 (ja) 2023-06-09
CN109790210B (zh) 2024-03-26
EP3464343A1 (en) 2019-04-10
JP2021088567A (ja) 2021-06-10
JP2019527533A (ja) 2019-10-03
MX2024008109A (es) 2024-07-19
CA3070789A1 (en) 2019-02-14
AR112357A1 (es) 2019-10-23
US11708418B2 (en) 2023-07-25
KR20240015159A (ko) 2024-02-02
JP2023041802A (ja) 2023-03-24
TW201910349A (zh) 2019-03-16
MX2024005669A (es) 2024-05-30
US20240132616A1 (en) 2024-04-25
EP4296680A2 (en) 2023-12-27
EP4296680A3 (en) 2024-03-20
EP3587445A1 (en) 2020-01-01
BR112020002636A2 (pt) 2020-07-28
EA202090265A1 (ru) 2020-06-05
AU2023204121B2 (en) 2026-04-23
PL3587445T3 (pl) 2024-04-29
HUE065510T2 (hu) 2024-05-28
AU2018313028B2 (en) 2023-05-25
AU2023204121A1 (en) 2023-07-20
ES2911243T3 (es) 2022-05-18
PT3587445T (pt) 2024-03-14
EP3464343B1 (en) 2022-03-23
JP6833851B2 (ja) 2021-02-24
ES2973864T3 (es) 2024-06-24
CN109790210A (zh) 2019-05-21
KR20200035194A (ko) 2020-04-02
WO2019030581A1 (en) 2019-02-14
MX2020001489A (es) 2020-03-20
EP3587445B1 (en) 2023-12-13
UY37757A (es) 2018-11-30
US20240092929A1 (en) 2024-03-21
US20210198376A1 (en) 2021-07-01
KR102631281B1 (ko) 2024-01-30
AU2018313028A1 (en) 2020-02-20
US20240228651A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
CN109790210B (zh) 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
JP7847587B2 (ja) 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
JP7561775B2 (ja) 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
Greidinger et al. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen
JP2022022308A (ja) 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原
JP2023514270A (ja) 免疫グロブリン検出と関連する療法
BR122024021835A2 (pt) Composição para ligação a um anticorpo anti-cd47, kit para investigação de biomonitoramento e ensaios de diagnóstico, métodos para: neutralização ou bloqueio da ligação de um anticorpo anti-cd47, seleção de uma unidade adequada de hemácias e remoção de anti-cd47 no plasma, soro e/ou sangue humano, e proteína de fusão.
BR122024021803A2 (pt) Marcador de oligomerização para uma proteína de fusão recombinante, e proteína de fusão
Hancock et al. Production and characterization of antibodies against synthetic peptides
WO2009123145A1 (ja) パラスポリン－１受容体及びその用途
Sakamoto et al. Characterization of feline serum ferritin-binding proteins: the presence of a novel ferritin-binding protein as an inhibitory factor in feline ferritin immunoassay
WO2011068538A2 (en) General method for generating ultra-high affinity binding proteins
Ramezani et al. Efficient detection of eukaryotic calcium-sensing receptor (CaSR) by polyclonal antibody against prokaryotic expressed truncated CaSR
Acton Immunoglobulins—Advances in Research and Application: 2013 Edition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: 10808 Will Road, San Diego, California, USA

Applicant after: GRIFOLS DIAGNOSTIC SOLUTIONS Inc.

Address before: California, USA

Applicant before: GRIFOLS DIAGNOSTIC SOLUTIONS Inc.

Country or region before: U.S.A.